Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy
- PMID: 18786780
- DOI: 10.1016/j.ijrobp.2008.03.062
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy
Abstract
Purpose: To determine prognostic factors for local control of primary or metastatic tumors within the lung or liver treated with stereotactic body radiation therapy (SBRT) within a single institution.
Methods and materials: The records of 141 consecutive patients with 246 lesions treated with three-fraction SBRT from Oct 1999 through Aug 2005 were reviewed. Local control was assessed radiographically. Univariate and multivariate analyses were performed to evaluate the influence of the following factors on local control: total dose, expressed as either nominal prescription dose or equivalent uniform dose (EUD); gross tumor volume; primary site; treatment site (lung vs. other); histologic characteristics (adenocarcinoma vs. other); gender; age; and primary vs. metastatic tumor.
Results: On univariate analysis, increased dose (either nominal or EUD) and smaller gross tumor volume were significant predictors of higher local control. Lesions treated to a nominal dose of 54 Gy or greater had a 3-year actuarial local control rate of 89.3% compared with 59.0% and 8.1% for those treated to 36-53.9 Gy and less than 36 Gy. On multivariate analysis, only increased nominal dose and EUD retained statistical significance. Treatment was well tolerated; 5.7% of patients experienced Grade 3 or higher toxicity.
Conclusions: This large single-institution series suggests a dose-control relationship within the range of SBRT doses applied. Excellent local control rates are achieved with a nominal dose of 54 Gy or greater, corresponding to an EUD greater than 65.3 Gy. These results support the use of aggressive SBRT regimens when durable tumor control is the primary objective.
Similar articles
-
Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.Acta Oncol. 2009;48(4):571-7. doi: 10.1080/02841860802520821. Acta Oncol. 2009. PMID: 19031164
-
Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer.Jpn J Clin Oncol. 2010 Feb;40(2):125-9. doi: 10.1093/jjco/hyp129. Epub 2009 Oct 12. Jpn J Clin Oncol. 2010. PMID: 19825814
-
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.J Clin Oncol. 2009 Apr 1;27(10):1572-8. doi: 10.1200/JCO.2008.19.6329. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255321 Clinical Trial.
-
Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases.Semin Radiat Oncol. 2006 Apr;16(2):77-84. doi: 10.1016/j.semradonc.2005.12.003. Semin Radiat Oncol. 2006. PMID: 16564443 Review.
-
Stereotactic body radiation therapy for liver metastases.Eur J Cancer. 2009 Nov;45(17):2947-59. doi: 10.1016/j.ejca.2009.08.011. Epub 2009 Sep 19. Eur J Cancer. 2009. PMID: 19773153 Review.
Cited by
-
Conformal Avoidance of Normal Organs at Risk by Perfusion-Modulated Dose Sculpting in Tumor Single-Dose Radiation Therapy.Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):288-297. doi: 10.1016/j.ijrobp.2020.08.017. Epub 2020 Aug 7. Int J Radiat Oncol Biol Phys. 2021. PMID: 32777335 Free PMC article. Clinical Trial.
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.Clin Cancer Res. 2020 Dec 15;26(24):6437-6444. doi: 10.1158/1078-0432.CCR-20-1790. Epub 2020 Oct 7. Clin Cancer Res. 2020. PMID: 33028595 Free PMC article. Clinical Trial.
-
Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases.Radiat Oncol. 2014 Jan 8;9:10. doi: 10.1186/1748-717X-9-10. Radiat Oncol. 2014. PMID: 24401323 Free PMC article.
-
Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.Radiother Oncol. 2017 Feb;122(2):286-294. doi: 10.1016/j.radonc.2016.11.006. Epub 2016 Nov 18. Radiother Oncol. 2017. PMID: 27871671 Free PMC article. Review.
-
A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases.Rep Pract Oncol Radiother. 2020 Nov-Dec;25(6):987-993. doi: 10.1016/j.rpor.2020.09.010. Epub 2020 Oct 2. Rep Pract Oncol Radiother. 2020. PMID: 33100916 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical